Durable Clinical Benefit in Patients with Advanced Cutaneous Melanoma after Discontinuation of Anti-PD-1 Therapies Due to Immune-Related Adverse Events

by Umang Swami, Varun Monga, Aaron D. Bossler, Yousef Zakharia, Mohammed Milhem
Published 2019-01-01

Multivariable Analysis of 169 Cases of Advanced Cutaneous Melanoma to Evaluate Antibiotic Exposure as Predictor of Survival to Anti-PD-1 Based Immunotherapies

by Umang Swami, Adithya Chennamadhavuni, Nicholas Borcherding, Aaron D. Bossler, Sarah L. Mott, Rohan Garje, Yousef Zakharia, Mohammed Milhem
Published 2020-10-01

Correction to: Genomics of NSCLC patients both affirm PD-L1 expression and predict their clinical responses to anti-PD-1 immunotherapy

by Kim A. Brogden, Deepak Parashar, Andrea R. Hallier, Terry Braun, Fang Qian, Naiyer A. Rizvi, Aaron D. Bossler, Mohammed M. Milhem, Timothy A. Chan, Taher Abbasi, Shireen Vali
Published 2018-04-01

Genomics of NSCLC patients both affirm PD-L1 expression and predict their clinical responses to anti-PD-1 immunotherapy

by Kim A. Brogden, Deepak Parashar, Andrea R. Hallier, Terry Braun, Fang Qian, Naiyer A. Rizvi, Aaron D. Bossler, Mohammed M. Milhem, Timothy A. Chan, Taher Abbasi, Shireen Vali
Published 2018-02-01

Melanoma Brain Metastases in the Era of Targeted Therapy and Checkpoint Inhibitor Therapy

by John M. Rieth, Umang Swami, Sarah L. Mott, Mario Zanaty, Michael D. Henry, Aaron D. Bossler, Jeremy D. Greenlee, Yousef Zakharia, Marion Vanneste, Brooke Jennings, Mohammed M. Milhem
Published 2021-03-01

TRAPPC11 and GOSR2 mutations associate with hypoglycosylation of α-dystroglycan and muscular dystrophy

by Austin A. Larson, Peter R. Baker, Miroslav P. Milev, Craig A. Press, Ronald J. Sokol, Mary O. Cox, Jacqueline K. Lekostaj, Aaron A. Stence, Aaron D. Bossler, Jennifer M. Mueller, Keshika Prematilake, Thierry Fotsing Tadjo, Charles A. Williams, Michael Sacher, Steven A. Moore
Published 2018-05-01